Reference
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial
Cao, Y., Wei, J., Zou, L., Jiang, T., Wang, G., Chen, L., Huang, L., Meng, F., Huang, L., Wang, N., Zhou, X., Luo, H., Mao, Z., Chen, X., Xie, J., Liu, J., Cheng, H., Zhao, J., Huang, G., Wang, W., … Zhou, J. (2020). Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial. The Journal of allergy and clinical immunology, 146(1), 137–146.e3. https://doi-org.proxy1.library.jhu.edu/10.1016/j.jaci.2020.05.019
0
1
Updated 2020-07-25
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences